Alira Health and GDMH together to boost Life Sciences innovation

The companies join forces for collaborative research and co-development of projects in the fields of Digital Health, Real-World Evidence and Market Access.

Alira Health, a global advisory and clinical research firm with the mission to humanize healthcare and life sciences, announces a new collaboration agreement signed with GDMH – Gemelli Digital Medicine & Health, part of Fondazione Policlinico Agostino Gemelli IRCCS (FPG) and prime provider of turn-key solutions in digital medicine and health in Italy. The goal of this partnership is to develop innovative solutions in the fields of Digital Health, Real-World Evidence (RWE) and Market Access in the best interest of research and patients, while ensuring the highest standards of data quality and protection.

We are thrilled to kick start this partnership with GDMH to accelerate the adoption of patient-centered technologies in our quest to humanize healthcare. We are joining forces with GDMH to build, in partnership with patients, digital health solutions that enable a full spectrum of use cases, including Decentralized Clinical Trials, Patient Support Programs, and DTx for pharma, MedTech, providers, and the payer community. Together GDMH and Alira Health bring a wealth of knowledge in clinical development, health tech, data science, market access, commercial strategy, and RWE.”
Piergiulio Lauriano Chief Strategy Officer at Alira Health
We at GDMH look forward to this collaboration in order to bring our digital solutions closer to the clinical research domain in a pragmatic and efficient way. It will help deepen each party's capabilities and bring lessons and solutions to GDMH, the healthcare and Pharma industries, as well as to the medical community and patients, and possibly to other industry sectors.”
Alfredo Cesario Chief Executive Officer at GDMH
Alira Health and GDMH will collaborate together in the fields of Digital Health, RWE and Market Access to co-develop innovative solutions in the best interests of research and patients. Thanks to this partnership, we will be able to merge our know-how, network, and capabilities, to explore the use of innovative digital health solutions and enable a full spectrum of use cases of joint value for both GDMH and Alira Health.”
Jean-François Ricci Chief Access Officer at Alira Health
About Alira Health

Alira Health is a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, in partnership with patients, through innovative technologies and expert guidance. From development to medical care, Alira Health complements the expertise of its Pharma, Biotech, and MedTech clients with a full spectrum of services across their entire solutions lifecycle.

Learn more:

About GDMH – Gemelli Digital Medicine & Health

Gemelli Digital Medicine & Health (GDMH), a company fully owned by Fondazione Policlinico Gemelli, is a prime integrator and provider of turn-key solutions in Digital Medicine and Health. First movers in the market with the profile of a large general hospital spin off we co-create together with the best players in the Digital Medicine scenario, deploy and manage advanced digital medical solutions worldwide with complete ethical, technical, and legal credentials.

Learn more:

Related news

Events February 21, 2024
XXII Conferenza Nazionale Sulla Farmaceutica
Meet Giovanni Firenze, Partner Consulting Italy, onsite in Catania and learn more about the impact of the new AIFA reform.
Italy Regulatory
Events February 20, 2024
World EPA Congress Europe
Look for market access and pricing experts Ahmad Bechara and Andrea Mantovani representing Alira Health on the agenda at World EPA Congress.
Market Access Pricing Real-World Evidence (RWE)
Publications February 15, 2024
FDA Approves GAMMAGARD LIQUID Based on Safety Data From an RWE Study
Food and Drug Administration (FDA) approves GAMMAGARD LIQUID based on safety data from a real-world evidence study.
Real-World Evidence (RWE) RWE Decision Alert
Publications February 9, 2024
UK HTA Recommends KANUMA in Pediatric Patients Based Partly on Comparative RWD
KANUMA underwent a recent appraisal by the UK's NICE for the treatment of Wolman disease in children aged two years and under.
Real-World Evidence (RWE) RWE Decision Alert
Publications February 1, 2024
French HTA Maintains Reimbursement of HyQvia in Adults and Extends Reimbursement to Children, Largely Driven by RWE
French HTA maintains reimbursement of HyQvia in adults and extends reimbursement to children, largely driven by RWE.
Real-World Evidence (RWE) RWE Decision Alert
News January 24, 2024
Alira Health and AseBio Announce Market Access Mentoring Program for 2024
Alira Health and AseBio, the Spanish Bioindustry Association, are pleased to announce the 2024 edition of their market access mentoring program for AseBio members.
Biotech Market Access Spain Startups
Case Studies January 18, 2024
Pharma Company Succeeds in Adding Medicine to World Health Organization Essential Medicines List
A pharma company with a blood disorder treatment needed support to submit a value dossier to the WHO to add a medicine to the Essential Medicines List.
Market Access Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.